Category: Patient Education

Dr. Richard Furman Discusses Recent Chronic Lymphocytic Leukemia Research Highlights

In this video from Patient Power, CLL Program Director, Dr. Richard Furman discusses recent results on chronic lymphocytic leukemia (CLL) presented in abstracts during the 2015 meeting of the American Society of Hematology (ASH) and the place of newly targeted therapies including ABT-199 and ACP-196 in treating patients with CLL.

Dr. Furman has previously written about CLL abstracts from the 2015 ASH meeting here and here. More information about available CLL trials at Weill Cornell Medicine can be found on the Joint Clinical Trials website.

Ibrutinib—A New Standard Treatment for Mantle Cell Lymphoma?

In The Lancet, Dr. Peter Martin commented on the results of a recently completed phase 3 trial in Europe that compared ibrutinib to temsirolimus among patients with mantle cell lymphoma. He writes that the results of the study clearly establish, “…ibrutinib as a new standard for treatment of relapsed mantle cell lymphoma.” Dr. Martin’s full comments on the topic can be found in the attached PDF below:

Ibrutinib-a new standard treatment for relapsed mantle cell lymphoma?

A full listing of currently available clinical trials for mantle cell lymphoma can be found on the Joint Clinical Trials website.

Dr. John Leonard Discusses New Data from PYRAMID Study on Non-Germinal Center B-Cell-Like Subtype Diffuse Large Cell Lymphoma

In this video from the ASCO Post, Lymphoma Program Director, Dr. John Leonard discusses results presented at the 2015 meeting of the American Society of Hematology from the recently completed Pyramid trial.  This multi-center phase II study sought to determine whether R-CHOP was more effective with or without bortezomib in patients with untreated non-germinal center B-cell-like subtype diffuse large cell lymphoma. (non-GCB DLBCL)

The study’s full abstract can be read here.